HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enroll...

Full description

Bibliographic Details
Main Authors: Beatriz Mothe, Miriam Rosás-Umbert, Pep Coll, Christian Manzardo, Maria C. Puertas, Sara Morón-López, Anuska Llano, Cristina Miranda, Samandhy Cedeño, Miriam López, Yovaninna Alarcón-Soto, Guadalupe Gómez Melis, Klaus Langohr, Ana M. Barriocanal, Jessica Toro, Irene Ruiz, Cristina Rovira, Antonio Carrillo, Michael Meulbroek, Alison Crook, Edmund G. Wee, Jose M. Miró, Bonaventura Clotet, Marta Valle, Javier Martinez-Picado, Tomáš Hanke, Christian Brander, José Moltó, The BCN02 Study Investigators
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Immunology
Subjects:
romidepsin
HDAC inhibitor
kick&kill strategy
HIVconsv
early-treatment
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00823/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00823/full

Similar Items